oversold, page-4

I agree totally - $145M of Pfizers money says BLT is quality. They had their pointy heads research ddRNAi for a year - then chief pointy head would have submitted his report to the Pfizer board complete with recommendation in the exec summary 'Go with ddRNAi'.

Up until the Tacere spin off which was forced upon BLT due to lack of funds and v.low sp, all this work and potential was totally BLT's.

Current BLT management are very good - they didn't offload the golden goose in the fire sale. And they know there's a lot more latent value to be released upon favourable outcomes in the CoH HIV stem cell trials, USPTO decision then onto the T cell HIV IND filing and subsquent PI trial.

Whilst it excites up the ST traders this stock is looking like it may prove a gem of a long term play.